Johnson & Johnson (JNJ), Friday announced its decision to discontinue Phase 2 field study, evaluating the efficacy of Mosnodenvir, formerly JNJ-1802, for the prevention of dengue virus in adults aged 18 to 65 years.
The decision comes as a part of a strategic reprioritization of the company's Communicable Diseases research and development portfolio.
Previously, phase 1 and phase 2a clinical studies found the investigational antiviral compound to be safe and well tolerated.
The company added that the efficacy data from phase 2 field study will be soon published after the completion of the ongoing final data analyses.
Currently, JNJ's stock is trading at $159.24, down 0.78 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.